Texas
LATEST FROM BIOSPACE
Pattern Bioscience was awarded funding from CARB-X to develop a new rapid diagnostic for drug-resistant bacterial infection.
Researchers are constantly finding drug combinations that help fight drug-resistant cancers. Researchers at the UT Southwestern Medical Center appeared to have found a new one using already approved drugs.
There were plenty of clinical trial announcements this week. Here’s a look.
A recent study questions if the FDA and other regulatory agencies worldwide rush certain approvals, particularly at the end of the year in a kind of “desk-clearing” activity.
BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.
“We are pleased that the FDA recognized Molgradex as a breakthrough therapy for the treatment of aPAP, a debilitating rare lung disease with no approved pharmacologic treatment options,” said Rob Neville, Savara’s chief executive officer.
What they found was that melanoma cells are more likely to metastasize through the body if their cells have high concentrations of MCT1 on their cell surface.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
In March, the FDA issued a Complete Response Letter for Zynquista as a treatment for type 1 diabetes.
PRESS RELEASES